Pharmaceutical Technology

MAY 25, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1.

Biobanking 130

Biobanking Genetics Genome Project Genome 130

pharmaphorum

JANUARY 24, 2023

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

Genetics 98

Genetics Drugs Genome Project Biobanking 98

pharmaphorum

JULY 28, 2022

. “We are currently testing this hypothesis, with the goal of pursuing a development candidate targeting INHBE in the near future,” said Paul Nioi, head of Alnylam’s human genetics group. The post Alnylam finds belly fat gene and drug target in UK Biobank study appeared first on.

Biobanking 52

Biobanking Gene Gene Silencing Drugs 52

XTalks

FEBRUARY 4, 2021

The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Biobanks are used for the coordination of high-yield patient sample collection. Generation of strong research dataset cohorts must begin with high-quality clinical samples.

Research 98

Research Biobanking Drugs Genomics 98

pharmaphorum

JANUARY 26, 2023

We are already seeing an increase in projects exploring population genomics in Africa, the Middle East, and Asia, with initiatives including the GenomeAsia100K Project and the Genome Aggregation Database focusing on capturing genetic data of non-European individuals.

Genome 129

Genome Genomics Genome Project Genetics 129

The Pharma Data

JULY 8, 2021

Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE).

Genetics 52

Genetics Biobanking Protein Containment 52

pharmaphorum

DECEMBER 2, 2021

It will focus its efforts initially on neurological diseases like Alzheimer’s and Parkinson’s, using technologies that can measure how disease alters tissues, cells and proteins, with the aim of increasing the success rate of drug discovery and development. Milestone payments tied to progress of the two drugs could add another $1.5

Biobanking 93

Biobanking Genome Genomics Genetics 93